

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023182 A1

(51) International Patent Classification:

A61K 31/48 (2006.01) F26B 5/06 (2006.01)
A61K 9/19 (2006.01) A61P 25/28 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2022/040636

(22) International Filing Date:

17 August 2022 (17.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/234,773 19 August 2021 (19.08.2021) US

(71) Applicant: **MIND MEDICINE, INC.** [US/US]; One
World Trade Center, Suite 8500, New York, New York
10007 (US).

(72) Inventors: **MACK, Peter**; 201 Old Larkspur Way, Chapel
Hill, North Carolina 27516 (US). **TRENKTROG, Timm**;


Buendtenweg 77, 4102 Binningen (CH). **MELTON,
Dustin**; 201 Emerson Drive, Melbane, North Carolina
27302 (US). **DOTY, Bethany Amber**; 276 Heathwood Drive,
Clayton, North Carolina 27527 (US). **SCHROEDER,
Jon**; 617 South Brearly Street, Madison, Wisconsin 53703
(US). **GARRETT, Lisa Marie**; Frankland Road, Blagrove,
Swindon SN5 8RU (GB).

(74) Agent: **KOHN, Kenneth L.**; 30500 Northwestern Highway,
Suite 410, Farmington Hills, Michigan 48334 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF D-LYSERGIC ACID DIETHYL-
LAMIDE FOR THERAPEUTIC APPLICATIONS

FIGURE 1



C₂₄H₃₁N₃O₇
Mol. Wt.: 473.52

D-LSD D-Tartrate

(57) Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*